Literature DB >> 11344546

Serum heat-labile opsonins in systemic lupus erythematosus.

H E Jasin1, J H Orozco, M Ziff.   

Abstract

To study possible mechanisms responsible for the increased susceptibility to infection of patients with active systemic lupus erythematosus (SLE), a study of the serum heat-labile opsonic capacity (HLOC) in such patients was undertaken. With leukocytes from normal donors, the sera of 12 of 30 patients with active SLE demonstrated decreased HLOC for E. coli 075. The phagocytic activity was partially restored by normal serum, suggesting that decreased HLOC was responsible for the defective phagocytosis. While 8 of 10 patients with active SLE and concomitant infections showed deficient opsonic capacity to E. coli 075, only 4 of 20 such patients without infections showed the defect (P = 0.01). None of 12 patients with inactive disease had deficient opsonic capacity. Similar results were obtained with S. aureus 502A as the test bacterium. In the patients surviving infection, recovery of normal serum opsonic capacity was rapid and usually coincided with an increase of serum complement to normal levels. In three patients with active SLE and infection, the causative microorganisms were isolated and opsonic capacity for these organisms tested with the individual patients' sera. In each case, sera obtained at the onset of the infectious episode had low opsonic capacity when compared with normal sera. Serum C3 proactivator levels were low in 9 of 11 sera with deficient opsonic capacity. However, similar low values were found in other SLE sera with normal HLOC, suggesting that other factors of the opsonic system were also depleted. Addition of the classical complement components C1, C4, C2, C3, and C5 to sera with deficient HLOC failed to restore activity. Addition of pure C3 proactivator also failed to restore activity. However, addition of C3 proactivator together with 50 degrees C-heated normal serum restored activity, indicating that factors active at the early steps of opsonic activation via the alternative pathway of complement were necessary to restore opsonic activity. These findings indicate that in active SLE, a decrease of components of the alternate pathway of complement activation results in an acquired defect of serum HLOC and perhaps other related complement-mediated functions. This defect may be an important factor in the increased susceptibility to infections of patients with active systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 11344546      PMCID: PMC301475          DOI: 10.1172/JCI107566

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Phagocytosis, with particular reference to encapsulated bacteria.

Authors:  W B WOOD
Journal:  Bacteriol Rev       Date:  1960-03

2.  Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus.

Authors:  L Brandt; H Hedberg
Journal:  Scand J Haematol       Date:  1969

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Improved tests for the evaluation of neutrophil function in human disease.

Authors:  J W Alexander; D B Windhorst; R A Good
Journal:  J Lab Clin Med       Date:  1968-07

5.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

6.  Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia.

Authors:  H Gewurz; A R Page; R J Pickering; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

7.  Decreased 19S antibody response to bacterial antigens in systemic lupus erythematosus.

Authors:  J Baum; M Ziff
Journal:  J Clin Invest       Date:  1969-04       Impact factor: 14.808

8.  Heat labile opsonins to pneumococcus. I. Participation of complement.

Authors:  M R Smith; W B Wood
Journal:  J Exp Med       Date:  1969-12-01       Impact factor: 14.307

9.  Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement.

Authors:  W Dias Da Silva; I H Lepow
Journal:  J Exp Med       Date:  1967-05-01       Impact factor: 14.307

10.  The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors.

Authors:  R B Johnston; M R Klemperer; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  7 in total

1.  The effect of complement depletion on lung clearance of bacteria.

Authors:  G N Gross; S R Rehm; A K Pierce
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

2.  Absence of the eighth component of complement in association with systemic lupus erythematosus-like disease.

Authors:  H E Jasin
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

3.  Correlation of disease activity and Clq-binding immune complexes with the neutrophil inclusions which form in the presence of SLE sera.

Authors:  E R Hurd; H E Jasin; J N Gilliam
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

Review 4.  Phagocytosis. Clinical disorders of recognition and ingestion.

Authors:  T P Stossel
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

5.  A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.

Authors:  H D Perez; M Lipton; I M Goldstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

6.  Reduced opsonisation of protein A containing Staphylococcus aureus in sera with cryoglobulins from patients with active systemic lupus erythematosus.

Authors:  O Nived; C Linder; H Odeberg; B Svensson
Journal:  Ann Rheum Dis       Date:  1985-04       Impact factor: 19.103

7.  Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure.

Authors:  R J Wyke; I A Rajkovic; A L Eddleston; R Williams
Journal:  Gut       Date:  1980-08       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.